Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Anna Protopapas
|
| gptkbp:collaboratesWith |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Merck_KGaA |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
antibody-drug conjugates |
| gptkbp:foundedYear |
2001
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:numberOfEmployees |
~100 (as of 2023)
|
| gptkbp:platform |
Dolaflexin
Immunosynthen |
| gptkbp:products |
UpRi (Upifitamab rilsodotin)
XMT-1660 XMT-2056 |
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
MRSN
|
| gptkbp:website |
https://www.mersana.com/
|
| gptkbp:bfsParent |
gptkb:David_Elmaleh
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mersana Therapeutics
|